ArticleScientific reports2026
Type I interferon signaling defines a novel disease signature in xeroderma pigmentosum C human keratinocytes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Xeroderma Pigmentosum C (XPC) is a DNA damage recognition protein central to the global genome nucleotide excision repair (GG-NER) pathway, where it acts as a primary sensor of UV-induced DNA lesions. Loss-of-function mutations in the XPC gene lead to a photosensitive phenotype, with marked accumulation of unrepaired DNA damage and a dramatically elevated risk (10,000-fold) of skin cancer. However, understanding the molecular signaling mechanisms associated with XP-C has been hindered by the lack of reproducible disease models. Here, we overcome this challenge using our genetically engineered human XPC knockout (KO) keratinocytes, the predominant cell type affected by UV radiation. To uncover upstream signaling changes associated with the absence of XPC expression, we quantified protein tyrosine kinase (PTK) activity one-hour post-UVB exposure. XPC KO keratinocytes showed significant dysregulation of PTK activity on ~ 100 phosphosites compared to controls. Complementary mass spectrometry (MS)-based quantitative proteomic analysis performed 24 h post-UVB exposure identified a downstream signature comprising 791 differentially expressed proteins in XPC KO cells irradiated compared to non-irradiated counterparts. An integrative bioinformatic assessment of the kinase activity and proteomic data revealed a significant perturbation in type I interferon signaling via the JAK/STAT pathway in XPC-deficient keratinocytes, which is further exacerbated by UVB exposure. These findings were validated by western blot analysis, establishing a novel disease-associated molecular signature. Given the central role played by JAK/STAT signaling in inflammatory processes, our results implicate this pathway as a key mediator of XP-C’s hypersensitivity, thereby highlighting its potential to alleviate the disease pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.